Haresh Jhangiani

1.1k total citations
14 papers, 261 citations indexed

About

Haresh Jhangiani is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, Haresh Jhangiani has authored 14 papers receiving a total of 261 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Surgery and 4 papers in Molecular Biology. Recurrent topics in Haresh Jhangiani's work include Nausea and vomiting management (3 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Anesthesia and Pain Management (3 papers). Haresh Jhangiani is often cited by papers focused on Nausea and vomiting management (3 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Anesthesia and Pain Management (3 papers). Haresh Jhangiani collaborates with scholars based in United States, Switzerland and Spain. Haresh Jhangiani's co-authors include Eyal Meiri, James J. Vredenburgh, Hwa-Ming Yang, Luigi Barbato, Florence Dalenc, Elizabeth Tan-Chiu, Sara A. Hurvitz, Mario Campone, Tetiana Taran and Joseph Gligorov and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Breast Cancer Research and Treatment.

In The Last Decade

Haresh Jhangiani

14 papers receiving 247 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Haresh Jhangiani United States 6 113 67 62 41 34 14 261
Andreas Schwarzer Germany 11 78 0.7× 86 1.3× 104 1.7× 16 0.4× 39 1.1× 36 375
T. Lightfoot Germany 3 39 0.3× 34 0.5× 80 1.3× 39 1.0× 42 1.2× 3 399
Sarah Murray United States 9 106 0.9× 12 0.2× 60 1.0× 66 1.6× 28 0.8× 22 315
Kazumasa Suzuki Japan 11 109 1.0× 79 1.2× 36 0.6× 21 0.5× 15 0.4× 37 416
Eyal Meiri United States 8 110 1.0× 111 1.7× 29 0.5× 52 1.3× 3 0.1× 14 289
Anne M. Buunk Netherlands 10 17 0.2× 118 1.8× 76 1.2× 14 0.3× 22 0.6× 29 392
Daniela Ibarra Gasparini Italy 6 125 1.1× 14 0.2× 61 1.0× 26 0.6× 29 0.9× 6 317
Virgil S. Lucas United States 8 122 1.1× 135 2.0× 65 1.0× 97 2.4× 5 0.1× 12 422
Narinder Nangia United States 10 130 1.2× 16 0.2× 43 0.7× 14 0.3× 7 0.2× 16 353
Harun Toy Türkiye 12 17 0.2× 109 1.6× 47 0.8× 51 1.2× 12 0.4× 28 413

Countries citing papers authored by Haresh Jhangiani

Since Specialization
Citations

This map shows the geographic impact of Haresh Jhangiani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haresh Jhangiani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haresh Jhangiani more than expected).

Fields of papers citing papers by Haresh Jhangiani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haresh Jhangiani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haresh Jhangiani. The network helps show where Haresh Jhangiani may publish in the future.

Co-authorship network of co-authors of Haresh Jhangiani

This figure shows the co-authorship network connecting the top 25 collaborators of Haresh Jhangiani. A scholar is included among the top collaborators of Haresh Jhangiani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haresh Jhangiani. Haresh Jhangiani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Spektor, Tanya M., Alberto Bessudo, Haresh Jhangiani, et al.. (2022). Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen. Experimental Hematology. 114. 54–60. 3 indexed citations
2.
Manda, Sudhir, Habte Yimer, Stephen J. Noga, et al.. (2020). Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib. Clinical Lymphoma Myeloma & Leukemia. 20(11). e910–e925. 11 indexed citations
3.
Zelenetz, Andrew D., Deepa Jagadeesh, Vaishalee P. Kenkre, et al.. (2019). THE PI3Kδ INHIBITOR ME‐401 ± RITUXIMAB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND SMALL LYMPHOCYTIC LYMPHOMA (SLL). Hematological Oncology. 37(S2). 176–177. 5 indexed citations
4.
Zelenetz, Andrew D., Deepa Jagadeesh, Nishitha Reddy, et al.. (2019). Results of the PI3Kδ inhibitor ME-401 alone or with rituximab in relapsed/refractory (R/R) follicular lymphoma (FL).. Journal of Clinical Oncology. 37(15_suppl). 7512–7512. 12 indexed citations
5.
Zelenetz, Andrew D., Jacob D. Soumerai, Deepa Jagadeesh, et al.. (2018). Preliminary Safety and Efficacy Results with an Intermittent Schedule of the PI3kδ Inhibitor ME-401 Alone or in Combination with Rituximab for B-Cell Malignancies. Blood. 132(Supplement 1). 2893–2893. 13 indexed citations
6.
Berenson, James R., Tanya M. Spektor, Alberto Bessudo, et al.. (2018). Efficacy and safety of pomalidomide as a replacement therapy for lenalidomide for relapsed/refractory multiple myeloma patients refractory to a lenalidomide-containing combination regimen.. Journal of Clinical Oncology. 36(15_suppl). e20012–e20012. 1 indexed citations
7.
8.
Schrock, Alexa B., Sai‐Hong Ignatius Ou, Luis E. Raez, et al.. (2016). Missed clinical benefit due to false negatives in testing for EGFR T790M mutations in non-small cell lung cancer. Cancer Treatment and Research Communications. 9. 131–133. 1 indexed citations
9.
Hurvitz, Sara A., Florence Dalenc, Mario Campone, et al.. (2013). A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Research and Treatment. 141(3). 437–446. 58 indexed citations
10.
Meiri, Eyal, et al.. (2007). Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Current Medical Research and Opinion. 23(3). 533–543. 144 indexed citations
11.
Jhangiani, Haresh, et al.. (2006). (732). Journal of Pain. 7(4). S35–S35. 2 indexed citations
12.
Wertheim, M. S., Haresh Jhangiani, Gwendolyn Niebler, & Veena Charu. (2006). Finding an effective dose of fentanyl effervescent buccal tablets: Combined results of open-label titration. Journal of Clinical Oncology. 24(18_suppl). 18521–18521. 1 indexed citations
13.
Jhangiani, Haresh, et al.. (2005). Dronabinol or Ondansetron Alone and Combined for Delayed Chemotherapy-Induced Nausea and Vomiting (CINV).. Blood. 106(11). 5555–5555. 2 indexed citations
14.
Meiri, Eyal, Haresh Jhangiani, James J. Vredenburgh, et al.. (2005). Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting (CINV). Journal of Clinical Oncology. 23(16_suppl). 8018–8018. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andreas Schwarzer Breakdown of academic impact, for papers by T. Lightfoot Breakdown of academic impact, for papers by Sarah Murray Breakdown of academic impact, for papers by Kazumasa Suzuki Breakdown of academic impact, for papers by Eyal Meiri Breakdown of academic impact, for papers by Anne M. Buunk Breakdown of academic impact, for papers by Daniela Ibarra Gasparini Breakdown of academic impact, for papers by Virgil S. Lucas Breakdown of academic impact, for papers by Narinder Nangia Breakdown of academic impact, for papers by Harun Toy
Rankless by CCL
2026